Gracchi, Valentina http://orcid.org/0000-0002-0330-4283
van den Belt, Sophie M. http://orcid.org/0000-0003-2112-3635
Corpeleijn, Eva http://orcid.org/0000-0002-2974-3305
de Zeeuw, Dick http://orcid.org/0000-0003-3434-7777
Heerspink, Hiddo J. L. http://orcid.org/0000-0002-3126-3730
Verkade, Henkjan J. http://orcid.org/0000-0002-7034-2861
Funding for this research was provided by:
Hutchison Whampoa Limited
Rijksuniversiteit Groningen
Stichting Vrienden Beatrix Kinderziekenhuis (StBKZ.1304)
Article History
Received: 8 July 2022
Revised: 1 October 2022
Accepted: 2 October 2022
First Online: 27 January 2023
Declarations
:
: The study was approved by the Medical Research and Ethics Committee of the University Medical Center Groningen, and written informed consent was obtained for all participants.
: D.d.Z. is on advisory boards and/or speaker for Bayer, Boehringer Ingelheim, Fresenius, Mitsubishi-Tanabe, Travere Pharmaceuticals; in steering committees and/or speaker for AbbVie and Janssen; and Data Safety and Monitoring Committees for Bayer. H.J.L.H. is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk, and Retrophin. He received research support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. H.J.V. is a consultant for Ausnutria, Albireo AB, Mirum, Friesland Campina, Vivet, Intercept, GMP-Orphan, and Shire (each on ad interim basis), for which his institution is compensated. None of these activities are related to the topic of the present study. All other authors declare no competing interests. The results presented in this paper have not been published previously in whole or part, except as abstract.